COVID-19: Mortality rate (in time) An Analysis of Publicly Available Data from 11 Countries to Calculate the Mortality Rate of COVID-19

{"title":"COVID-19: Mortality rate (in time) \nAn Analysis of Publicly Available Data from 11 Countries to Calculate the Mortality Rate of COVID-19","authors":"","doi":"10.2174/2666796704666230410123425","DOIUrl":null,"url":null,"abstract":"\n\nIn December 2019, a new virus, COVID-19, initially found in China, started spreading worldwide, resulting in a severe pandemic with 82 million confirmed infections at the end of 2020 and 288 million at the end of 2021. With 5.4 million reported deaths due to COVID-19 at the end of 2021, the apparent mortality rate is 2%, but the general agreement is that the reported numbers are incomplete. \nAn analysis was made on the publicly available COVID-19 data from eleven countries (8 in Europe, 2 in North America and 1 in Africa) to obtain a mortality rate for COVID-19. The data from these countries also contained information about hospital admissions and were partly available in graphics, allowing the data to be downloaded. The size of the population varied from 5 million (Norway) to more than 300 million (USA).\nData from an investigation of Sanquin, the Dutch blood bank, and the Belgian Red Cross on the presence of antibodies for the virus in their blood donors were used to estimate the number of infected people at the start of the pandemic. This estimate was combined with the number of hospital admissions to obtain a hospitalization rate. The resulting hospitalization rates for The Netherlands and Belgium were 1.49 % and 2.23 %, respectively. The hospitalization rates were used to calculate the total number of infected people during the pandemic, but analysis showed that the calculation is only valid until June 2021.\nUsing the Dutch and Belgian hospitalization rates, the available data from The Netherlands, Belgium and the United Kingdom showed that COVID-19 mortality rates of 1.2% at the start of the pandemic decreased to 0.4 % in the spring of 2021. \nThe resulting cumulative mortality rate in July 2021 showed agreement, within the uncertainty, for Germany, France, Switzerland, USA, Canada and South Africa, but with dependence on the use of the hospitalization rate. The mortality rate was below the uncertainty band in smaller countries like Denmark and Norway.\n","PeriodicalId":10815,"journal":{"name":"Coronaviruses","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Coronaviruses","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2666796704666230410123425","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

In December 2019, a new virus, COVID-19, initially found in China, started spreading worldwide, resulting in a severe pandemic with 82 million confirmed infections at the end of 2020 and 288 million at the end of 2021. With 5.4 million reported deaths due to COVID-19 at the end of 2021, the apparent mortality rate is 2%, but the general agreement is that the reported numbers are incomplete. An analysis was made on the publicly available COVID-19 data from eleven countries (8 in Europe, 2 in North America and 1 in Africa) to obtain a mortality rate for COVID-19. The data from these countries also contained information about hospital admissions and were partly available in graphics, allowing the data to be downloaded. The size of the population varied from 5 million (Norway) to more than 300 million (USA). Data from an investigation of Sanquin, the Dutch blood bank, and the Belgian Red Cross on the presence of antibodies for the virus in their blood donors were used to estimate the number of infected people at the start of the pandemic. This estimate was combined with the number of hospital admissions to obtain a hospitalization rate. The resulting hospitalization rates for The Netherlands and Belgium were 1.49 % and 2.23 %, respectively. The hospitalization rates were used to calculate the total number of infected people during the pandemic, but analysis showed that the calculation is only valid until June 2021. Using the Dutch and Belgian hospitalization rates, the available data from The Netherlands, Belgium and the United Kingdom showed that COVID-19 mortality rates of 1.2% at the start of the pandemic decreased to 0.4 % in the spring of 2021. The resulting cumulative mortality rate in July 2021 showed agreement, within the uncertainty, for Germany, France, Switzerland, USA, Canada and South Africa, but with dependence on the use of the hospitalization rate. The mortality rate was below the uncertainty band in smaller countries like Denmark and Norway.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID-19:死亡率(及时)对11个国家公开数据的分析,以计算COVID-19的死亡率
2019年12月,一种最初在中国发现的新型病毒COVID-19开始在全球传播,导致一场严重的大流行,到2020年底确诊病例达到8200万,到2021年底确诊病例达到2.88亿。截至2021年底,报告的COVID-19死亡人数为540万人,表观死亡率为2%,但普遍认为报告的数字不完整。对11个国家(欧洲8个、北美2个和非洲1个)公开获得的COVID-19数据进行了分析,以获得COVID-19的死亡率。来自这些国家的数据还包含有关住院情况的信息,部分以图表形式提供,允许下载这些数据。人口规模从500万(挪威)到3亿多(美国)不等。荷兰血库Sanquin和比利时红十字会对献血者体内是否存在病毒抗体的调查数据被用来估计大流行开始时的感染人数。这一估计数与住院人数相结合,得出住院率。结果,荷兰和比利时的住院率分别为1.49%和2.23%。住院率被用来计算大流行期间的感染总人数,但分析显示,该计算只适用于2021年6月。利用荷兰和比利时的住院率,荷兰、比利时和英国的现有数据显示,2019冠状病毒病死亡率在大流行开始时为1.2%,到2021年春季降至0.4%。由此得出的2021年7月累积死亡率在不确定性范围内与德国、法国、瑞士、美国、加拿大和南非一致,但取决于住院率的使用情况。丹麦和挪威等较小国家的死亡率低于不确定范围。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.50
自引率
0.00%
发文量
0
期刊最新文献
COVID-19 Vaccine Effectiveness on the Severity of Disease: A Case-control Study in Southeastern Iran Evaluation of Influenza Vaccination Coverage Among Healthcare Workers During the COVID-19 Pandemic and Analysis of Motivating and Hindering Factors Novel Coronavirus: An Overview of the History, Pathophysiology, Diagnosis, and Management of the Pandemic COVID-19 Catastrophe, with Special Emphasis on Herbal Treatment Alternatives Spectrum of Long COVID Symptoms and Management Approaches in Europe and Latin America Identification of Epitope Against Omicron Variant of SARS-CoV-2: In Silico Vaccine Design Approach
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1